Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Traws Pharma (TRAW) EPS (Weighted Average and Diluted) (2020 - 2025)

Traws Pharma's EPS (Weighted Average and Diluted) history spans 6 years, with the latest figure at -$0.71 for Q4 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at -$0.71 for Q4 2025, up 78.81% from a year ago — trailing twelve months through Dec 2025 was $0.93 (up 102.97% YoY), and the annual figure for FY2025 was $0.82, up 102.33%.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.71 at Traws Pharma, down from -$0.34 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $2.09 in Q1 2025 to a low of -$20.52 in Q2 2024.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$0.28 (2021), against an average of -$2.17.
  • The sharpest move saw EPS (Weighted Average and Diluted) plummeted 10160.0% in 2024, then soared 135.3% in 2025.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.16 in 2021, then tumbled by 62.5% to -$0.26 in 2022, then plummeted by 1815.38% to -$4.98 in 2023, then surged by 32.73% to -$3.35 in 2024, then surged by 78.81% to -$0.71 in 2025.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$0.71, -$0.34, and -$0.11 for Q4 2025, Q3 2025, and Q2 2025 respectively.